Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
PRVB Provention Bio, Inc. daily Stock Chart
PRVB [NASD]
Provention Bio, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.05 Insider Own4.70% Shs Outstand47.70M Perf Week0.36%
Market Cap740.89M Forward P/E- EPS next Y-1.68 Insider Trans0.66% Shs Float41.76M Perf Month5.87%
Income-44.90M PEG- EPS next Q-0.29 Inst Own21.90% Short Float6.73% Perf Quarter60.58%
Sales- P/S- EPS this Y-34.50% Inst Trans17.07% Short Ratio2.80 Perf Half Y-5.38%
Book/sh1.49 P/B9.32 EPS next Y-39.20% ROA-59.30% Target Price- Perf Year23.03%
Cash/sh1.44 P/C9.67 EPS next 5Y- ROE-63.60% 52W Range4.72 - 18.50 Perf YTD-6.78%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-24.92% Beta-
Dividend %- Quick Ratio11.30 Sales past 5Y- Gross Margin- 52W Low194.28% ATR1.29
Employees19 Current Ratio11.30 Sales Q/Q- Oper. Margin- RSI (14)46.03 Volatility7.43% 9.28%
OptionableYes Debt/Eq0.00 EPS Q/Q10.20% Profit Margin- Rel Volume0.84 Prev Close14.68
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume1.00M Price13.89
Recom1.70 SMA20-6.94% SMA501.05% SMA20021.64% Volume840,986 Change-5.38%
Jun-16-20Reiterated H.C. Wainwright Buy $20 → $26
Jun-04-20Initiated RBC Capital Mkts Outperform $25
Jun-04-20Initiated Oppenheimer Outperform $29
Jan-24-20Initiated Cantor Fitzgerald Overweight $25
Jun-26-19Reiterated H.C. Wainwright Buy $8 → $20
Jun-10-19Initiated Chardan Capital Markets Buy $20
Feb-22-19Initiated SVB Leerink Outperform $6
Jul-02-20 09:15AM  
Why This Under-the-Radar Biotech Stock Could Skyrocket
Motley Fool
Jun-30-20 04:30PM  
Provention Bio Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of the Stockholders
PR Newswire
Jun-29-20 07:00AM  
Provention Bio Announces Inclusion in the Russell 3000 Index and Russell 2000 Index
PR Newswire
Jun-22-20 04:01PM  
Provention Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire -5.91%
03:17PM  
Hedge Funds Are Selling Provention Bio, Inc. (PRVB)
Insider Monkey
Jun-19-20 10:26AM  
Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. +6.52%
Jun-17-20 10:16PM  
Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock
PR Newswire -6.76%
Jun-16-20 04:01PM  
Provention Bio Announces Proposed Public Offering of Common Stock
PR Newswire +5.46%
08:37AM  
Provention Bio (PRVB) Looks Good: Stock Adds 8.6% in Session
Zacks
Jun-15-20 05:02PM  
Why Provention Bio Jumped Today
Motley Fool +8.57%
12:02PM  
Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients
PR Newswire
May-28-20 07:00AM  
Provention Bio to Present at the Jefferies Virtual Healthcare Conference
PR Newswire
May-20-20 07:00AM  
Provention Bio Announces Changes to its Board of Directors
PR Newswire
May-18-20 07:00AM  
Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine
PR Newswire
May-08-20 07:30PM  
Provention Bio, Inc (PRVB) Q1 2020 Earnings Call Transcript
Motley Fool +14.56%
Apr-30-20 07:00AM  
Provention Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Thursday, May 7, 2020
PR Newswire
Apr-16-20 07:00AM  
Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
PR Newswire
Apr-01-20 09:09AM  
Provention Bio (PRVB) Soars: Stock Adds 6.4% in Session
Zacks -14.02%
Mar-21-20 08:54AM  
Insider Buying: The Provention Bio, Inc. (NASDAQ:PRVB) Co-Founder & Chief Scientific Officer Just Bought US$59k Worth Of Shares
Simply Wall St.
Mar-17-20 08:48AM  
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
Benzinga
Mar-16-20 04:05PM  
Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes
PR Newswire -15.87%
Mar-12-20 07:05AM  
Provention Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
PR Newswire -20.53%
07:00AM  
Provention Announces Positive Data from Phase 1b PREVAIL Study of PRV-3279
PR Newswire
Mar-05-20 07:00AM  
Provention Bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, March 12, 2020
PR Newswire
Feb-19-20 07:00AM  
Provention Bio to Present at Upcoming Conferences
PR Newswire
Feb-05-20 12:41PM  
Should You Take Comfort From Insider Transactions At Provention Bio, Inc. (NASDAQ:PRVB)?
Simply Wall St.
Jan-23-20 06:30AM  
Johnson & Johnson Sold a Hot Biotech Stock
Barrons.com
Jan-08-20 07:00AM  
Provention Bio Appoints Jason Hoitt as Chief Commercial Officer
PR Newswire
Dec-30-19 02:44PM  
Weekly CEO Buys Highlight
GuruFocus.com
Dec-17-19 05:19PM  
Hedge Funds Have Never Been This Bullish On Provention Bio, Inc. (PRVB)
Insider Monkey
Dec-12-19 07:00AM  
Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA
PR Newswire
Dec-05-19 06:15AM  
Boston investment firm led by former Bain Capital exec fuels diabetes research
American City Business Journals +5.52%
Dec-04-19 12:00PM  
Here's Why Momentum Investors Will Love Provention Bio, Inc. (PRVB)
Zacks
Nov-21-19 07:32AM  
Will Provention Bio Continue to Surge Higher?
Zacks
Nov-05-19 04:05PM  
Provention Bio Reports Third Quarter 2019 Financial Results
PR Newswire
Oct-29-19 12:52PM  
Will Provention Bio (NASDAQ:PRVB) Spend Its Cash Wisely?
Simply Wall St.
07:00AM  
Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019
PR Newswire
Oct-24-19 07:00AM  
Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
PR Newswire
Oct-22-19 07:00AM  
Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease
PR Newswire
Sep-26-19 07:00AM  
Sean Doherty Joins Provention Bio Board of Directors
PR Newswire
Sep-25-19 07:00AM  
Provention Bio to Present at the 2019 Cantor Global Healthcare Conference
PR Newswire
Sep-24-19 07:00AM  
Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing
PR Newswire
Sep-19-19 07:39AM  
The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO
Benzinga -14.18%
Sep-18-19 08:26PM  
Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock
PR Newswire
04:14PM  
Provention Bio Announces Proposed Public Offering of Common Stock
PR Newswire
Aug-27-19 03:30PM  
Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares
Simply Wall St.
Aug-20-19 07:00AM  
Provention Bio Announces Key Addition to its Leadership Team
PR Newswire
Aug-09-19 08:15AM  
Provention Bio Inc (PRVB) President and CEO Ashleigh Palmer Bought $96,990 of Shares
GuruFocus.com +7.61%
Aug-08-19 07:00AM  
Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus
PR Newswire
Aug-06-19 07:00AM  
Provention Bio Reports Second Quarter 2019 Financial Results
PR Newswire -10.27%
Aug-05-19 12:21PM  
A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019
Benzinga -6.76%
07:00AM  
Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals
PR Newswire
Jul-12-19 07:15AM  
5 Best Biotech Stocks of 2019 So Far
Motley Fool +6.48%
Jul-01-19 07:30AM  
ActoBio Therapeutics Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
PR Newswire
Jun-14-19 12:31PM  
Why Consistent Trading Doesn't Always Lead To Consistent Results
Benzinga
Jun-13-19 07:49AM  
Provention Bio Cancels Secondary Offering, Shares Rally
Benzinga -5.40%
07:27AM  
Provention Bio's stock surges after calling off public stock offering
MarketWatch
07:00AM  
Provention Bio Announces Termination of Public Offering of Common Stock
PR Newswire
Jun-12-19 08:44AM  
2 Small Biotechs With Sagging Shares but Promising Prospects
TheStreet.com
Jun-11-19 09:43AM  
Company News For Jun 11, 2019
Zacks -12.62%
07:34AM  
The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering
Benzinga
Jun-10-19 05:32PM  
Provention Bio Announces Proposed Public Offering of Common Stock
PR Newswire +217.01%
01:04PM  
Provention Bio News: Why PRVB Stock Is Skyrocketing Today
InvestorPlace
Jun-09-19 01:05PM  
A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years
PR Newswire
May-27-19 11:02AM  
Could The Provention Bio, Inc. (NASDAQ:PRVB) Ownership Structure Tell Us Something Useful?
Simply Wall St.
May-09-19 07:56AM  
The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut
Benzinga -27.45%
May-08-19 04:30PM  
Provention Bio Reports First Quarter 2019 Financial Results
PR Newswire
04:25PM  
Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
PR Newswire
Apr-24-19 07:00AM  
Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease
PR Newswire
Apr-12-19 09:49AM  
Provention Bio, Inc. (PRVB) Shares March Higher, Can It Continue?
Zacks
Apr-09-19 07:00AM  
Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
PR Newswire +15.95%
Apr-02-19 07:00AM  
Provention Bio Announces Key Additions to its Senior Management Team
PR Newswire
Mar-28-19 07:00AM  
Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors
PR Newswire
Mar-19-19 04:05PM  
Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
PR Newswire
Mar-12-19 04:05PM  
Provention Bio to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 19, 2019
PR Newswire
Feb-13-19 07:33AM  
Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference
PR Newswire +5.33%
Jan-28-19 07:33AM  
Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)
PR Newswire
Jan-03-19 07:33AM  
Provention Bio Announces Publication in "Expert Review of Vaccines" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B
PR Newswire
Dec-25-18 10:46AM  
Are Insiders Buying Provention Bio, Inc. (NASDAQ:PRVB) Stock?
Simply Wall St.
Nov-28-18 07:33AM  
Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium
PR Newswire
Nov-08-18 07:33AM  
Provention Bio Reports Third Quarter 2018 Financial Results and Provides Business Update
PR Newswire -6.47%
Nov-05-18 09:00AM  
Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
PR Newswire +13.00%
Oct-23-18 07:33AM  
Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis
PR Newswire -5.19%
Sep-11-18 07:33AM  
Provention Bio To Present at 2018 Janney Healthcare Conference
PR Newswire
Sep-05-18 07:33AM  
Provention Bio Appoints Accomplished Biotech Executive, Chip Catlin, to its Board of Directors
PR Newswire
Aug-13-18 08:00AM  
Provention Bio Reports Second Quarter 2018 Financial Results and Provides Business Update
PR Newswire +5.71%
Jul-31-18 07:33AM  
Provention Bio Appoints Leading T1D Expert, Dr. Mark Rigby, as Vice President, Clinical Development
PR Newswire
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leon FranciscoChief Scientific OfficerJun 24Buy15.432,00030,8622,565,450Jun 24 04:22 PM
Bluestone JeffreyDirectorApr 10Option Exercise2.3632,24676,10139,571Apr 14 05:00 PM
Leon FranciscoChief Scientific OfficerMar 19Buy5.9210,00059,2002,563,450Mar 20 06:15 AM
Hoitt JasonChief Commercial OfficerMar 19Buy5.434,50024,4354,500Mar 20 06:15 AM
Ramos EleanorCMO & COODec 26Buy14.342,00028,68062,000Dec 26 05:00 PM
Palmer AshleighPresident and CEODec 20Buy11.392,07523,6342,563,000Dec 23 04:30 PM
Leon FranciscoChief Scientific OfficerDec 16Buy11.922,00023,8402,553,450Dec 16 05:00 PM
open in yahoo | open in reuters | open in google